Evidence map›Paper›PMID 37534566›Full record

ArticleMacromolecular bioscience2023

Enhanced Maturation of 3D Bioprinted Skeletal Muscle Tissue Constructs Encapsulating Soluble Factor-Releasing Microparticles.

Natan Roberto de Barros, Mohammad Ali Darabi, Xin Ma, Sibel Emir Diltemiz, Menekse Ermis, Alireza Hassani Najafabadi, Sara Nadine, Ethan A Banton, Kalpana Mandal, Reza Abbasgholizadeh and 12 more

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Macromolecular bioscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Aligned Collagen Sponges Loaded With Myogenic Factors to Enhance Skeletal Muscle Tissue Regeneration.Journal of biomedical materials research. Part B, Applied biomaterials · 2025
    Article
  4. Extrusion bioprinting: meeting the promise of human tissue biofabrication?Progress in biomedical engineering (Bristol, England) · 2025
    Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 5 countries.

Natan Roberto de BarrosTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.ORCID 0000-0001-8689-4110
Mohammad Ali DarabiTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
Xin MaCenter for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Sibel Emir DiltemizDepartment of Chemistry, Eskisehir Technical University, Eskisehir, 26470, Turkey.
Menekse ErmisTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
Alireza Hassani NajafabadiTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
Sara NadineTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
Ethan A BantonCenter for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Kalpana MandalTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
Reza AbbasgholizadehTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
Natashya FalconeTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
João F ManoCICECO - Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, Campus Universitário de Santiago, Aveiro, 3810-193, Portugal.
Rohollah NasiriTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
Rondinelli Donizetti HerculanoTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
Yangzhi ZhuTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
Serge OstrovidovDepartment of Radiological Sciences, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Junmin LeeTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
Han-Jun KimTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
Vahid HosseiniTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
Mehmet R DokmeciTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
Samad AhadianDepartment of Bioengineering, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
Ali KhademhosseiniTerasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.ORCID 0000-0002-2692-1524
Terasaki Foundation · USUniversity of California, Los Angeles · USEskisehir Technical University · TRKorea University · KRPohang University of Science and Technology · KRUniversity of Aveiro · PT

Funding

Drug eluting injectable biomaterials for next generation chemoembolizationR01CA257558 · NCI · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2021 to 2025
$3.2M
Healing enterocutaneous fistulas using bioengineered biomaterialsR01DK130566 · NIDDK · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2022 to 2025
$2.2M
3D printed muscle-bone organ implant for treating large injuriesR01AR073135 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DOKMECI, MEHMET REMZI, JANG, HAE LIN · 2018 to 2022
$2.2M
NCI NIH HHS R01 CA257558NIAMS NIH HHS AR073135NIAMS NIH HHS R01 AR073135NIDDK NIH HHS 1R01DK130566-01NIDDK NIH HHS R01 DK130566
6 · The paper itself

Abstract

Several microfabrication technologies have been used to engineer native-like skeletal muscle tissues. However, the successful development of muscle remains a significant challenge in the tissue engineering field. Muscle tissue engineering aims to combine muscle precursor cells aligned within a highly organized 3D structure and biological factors crucial to support cell differentiation and maturation into functional myotubes and myofibers. In this study, the use of 3D bioprinting is proposed for the fabrication of muscle tissues using gelatin methacryloyl (GelMA) incorporating sustained insulin-like growth factor-1 (IGF-1)-releasing microparticles and myoblast cells. This study hypothesizes that functional and mature myotubes will be obtained more efficiently using a bioink that can release IGF-1 sustainably for in vitro muscle engineering. Synthesized microfluidic-assisted polymeric microparticles demonstrate successful adsorption of IGF-1 and sustained release of IGF-1 at physiological pH for at least 21 days. Incorporating the IGF-1-releasing microparticles in the GelMA bioink assisted in promoting the alignment of myoblasts and differentiation into myotubes. Furthermore, the myotubes show spontaneous contraction in the muscle constructs bioprinted with IGF-1-releasing bioink. The proposed bioprinting strategy aims to improve the development of new therapies applied to the regeneration and maturation of muscle tissues.

Indexed as

BioprintingTissue ScaffoldsGelatinHydrogelsInsulin-Like Growth Factor IMuscle Fibers, SkeletalMuscle, SkeletalPrinting, Three-DimensionalTissue EngineeringGelatinHydrogelsInsulin-Like Growth Factor I3D bioprintingdrug releasegelatin methacryloyl (GelMA)IGF-1microfluidicsmicroparticlemuscle tissue engineering

Identifiers

PMID37534566
PMCPMC10837326
OpenAlexW4385514675

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.